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Nonalcoholic steatohepatitis has become one of the most common liver-related health problems. This condition has been linked
to an unhealthy diet and weight gain, but it can also be observed in nonobese people. The standard of care is represented by
the lifestyle intervention. However, because this approach has several limitations, such as a lack of compliance, the use of many
drugs has been proposed. The first-line pharmacological choices are vitamin E and pioglitazone, both showing a positive effect
on transaminases, fat accumulation, and inflammation. Nevertheless, vitamin E has no proven effect on fibrosis and on long-term
morbidity and mortality and pioglitazone has a negative impact on weight. Other drugs have been studied such as metformin,
ursodeoxycholic acid, statins, pentoxiphylline, and orlistat with only partially positive results. Among the emerging treatments,
telmisartan is particularly interesting as it seems to have an impact on insulin resistance, liver steatosis, inflammation, and fibrosis.
However, the pathogenesis of steatohepatitis is highly complex and is determined by different parallel hits; indeed, the association
of different drugs that act on various levels has been suggested. In conclusion, lifestyle intervention should be optimised and the
associations of different drugs should be tested in large studies with long-term outcomes.
1. Introduction
1.1. Definition and Aim. We define “nonalcoholic fatty liver
disease (NAFLD)” as hepatic steatosis that accounts for
more than 5–10% of the total hepatic weight. To make
an accurate diagnosis, imaging or histological techniques
are necessary, and other causes of fat accumulation should
be excluded such as the excessive consumption of alcohol
(women ≤20 g/d, men ≤30 g/d). Moreover, other causes of
secondary macrovesicular steatosis should be explored such
as parenteral nutrition, hepatitis C, Wilson’s disease, states
of hunger, lipodystrophy, abetalipoproteinemia, and drugs
(e.g., methotrexate, amiodarone, and steroids). Furthermore,
clinicians should search for other origins of microvesicular
steatosis such as Reye’s syndrome, acute fatty liver of preg-
nancy, HELLP syndrome, metabolic disorders (e.g., lecithin-
cholesterol-acyltransferase deficiency), and the use of drugs
(e.g., antiretroviral drugs or valproate) [1].
Notably, NAFLD is considered to be the hepatic manifes-
tation of metabolic syndrome, as it is strongly associated with
insulin resistance (IR), central obesity, reduced glucose toler-
ance, type 2 diabetes mellitus (T2DM), arterial hypertension,
and hypertriglyceridaemia [2].
However, when we refer to NAFLD, a wide spectrum of
disorders is included, ranging from simple nonalcoholic fatty
liver (NAFL) to nonalcoholic steatohepatitis (NASH); these
disorders are characterised not only by an inflammatory con-
dition, ballooning degeneration, necroapoptosis, and fibrosis
but also by a relevant impact on morbidity and mortality [1].
In this review, we analyse the relationship between the
complex molecular aspects of NASH and the most interest-
ing and promising treatment options. The literature search
included published articles (peer-reviewed original, review,
and meta-analyses) with a strong priority for randomised
controlled trials (RCT). The search terms included “NAFLD
and therapy,” “NASH and therapy,” “NAFLD and treatment,”
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“NASH and treatment,” “NAFLD and drug,” and “NASH and
drug.”
1.2. Epidemiology. In the last several years, NAFLD has
continued to increase worldwide and is the most common
reason for irregular liver tests in both developed and emerg-
ing countries [3]. Today, in both Europe and the United
Kingdom, NAFLD represents the most frequent cause of
chronic liver disease [4, 5]. It was reported that NASH affects
approximately 1% of the European and North-American
population, and longitudinal studies demonstrated that the
histological patterns worsen in approximately one-third of
patients who are at risk of progression to cirrhosis [6]. In the
United States (US), according to the “National Health and
Nutrition Examination Survey,” the proportion of NAFLD
among chronic liver diseases increased from 47% to 75%
between 1988 and 2008.The rationale for this increase is most
likely an increase in metabolic risk factors. In fact, in the
same time period, the prevalence of obesity, visceral obesity,
T2DM, IR, and arterial hypertension increased [7], and it is
well known that patients with NAFL are also more likely to
be obese (from 30% to 100%) and have T2DM (from 10% to
75%) [7].
According to the “Organization for Economic Coopera-
tion andDevelopment,” in 2000, 11.5% of German adults were
obese, while ten years later, the percentage increased to 14.7%
[8]. It was also reported that, in Europe, approximately one-
third of adults exhibit a pattern ofNAFLD [5].The prevalence
ranges between 13.9% and 26.6% and is based on whether the
newest technology (i.e., ultrasound) is used in the screening
[9]. However, if we analyse several subgroups such as patients
who are affected by T2DM, we find that 44% of patients
exhibit a pattern reminiscent of NAFLD [5]. Interestingly,
for reasons that are not completely clear, an increase in the
prevalence ofNAFLDwas recently cited among younger (e.g.,
12.8% in Australia) and older people (35% in Netherlands)
[10, 11].
When the attended variance that is related to the diag-
nostic methods is considered in the available studies, the
global prevalence of NAFLD ranges from 6% to 33%, while
the prevalence of NASH is notably lower (3%–5%) [12].
Although many epidemiological studies have shown that
NAFLD is strictly connected to an unhealthy diet and seden-
tary behaviours [13], metabolic liver disease can also be found
in nonobese populations [14]. Specifically, Caldwell et al.
[15] reported that both ethnicity and genetic polymorphisms
could play a central role in the development of this disease.
1.3. Molecular Aspects. Traditionally, the pathogenesis of
NAFLD was conceived as a “two-hit” process [16]: (a) the
accumulation of lipids in hepatocytes promotes IR, which is
the key factor for the development of hepatic steatosis; (b) the
consequences are an increase in proinflammatory cytokines
and adipokines, mitochondrial dysfunction, oxidative stress,
and endoplasmic reticulum stress, which lead to hepatocyte
injury, inflammation, and fibrosis. In the past few years,
many authors [17, 18] have reported that NASH is associated
with a significantly worse outcome with respect to simple
steatosis. Indeed, it has been suggested that NASH and simple
steatosis should be considered two separate diseases. After
consideration of the progressive form of NAFLD, which is
definitively represented by NASH, a new and more realistic
model was proposed: the “multiparallel hits” hypothesis [19].
Themain concept that has emerged from this new idea is that
different events occur that in turn determine liver damage,
but these events take place in parallel, not consecutively.
Remarkably, all of the events that favour the pathogenesis of
NASH are potentially therapeutic targets. We can consider
the following elements as the main pathological protagonists:
IR, oxidative stress, gut, adipose and pancreas tissues, altered
lipid metabolism, bile acids, gut microbiota, and bacterial
endotoxins. It is important to underline that all the mech-
anisms of damage that are involved in the pathogenesis
of NASH enhance two conditions that are central in the
progression ofNASH: IR and systemic chronic inflammation.
The molecular basis of IR is the result of both genetic and
nongeneticmechanisms.However, IR initiates a vicious circle
that leads to inflammation, hypercoagulability, and atheroge-
nesis. Interestingly, IR develops in the vasculature earlier than
in muscle, liver, or adipose tissue, and this explains the high
cardiovascular risk that can be found in patients with IR [20].
Tumour necrosis factor-alpha (TNF-𝛼) plays an important
role in the development of an inflammatory state, determines
apoptotic and fibrogenic reactions, and regulates IR [21]. In
addition, oxidative stress is considered to be an important
stage in the development of NASH. Oxidative stress is due
to mitochondrial dysfunction and represents a true turning
point for many investigators.The loss of electrons from com-
plexes I and III in the mitochondrial electron transport chain
can combine with oxygen, which generates reactive oxygen
species; these promote damage to theDNA, lipidmembranes,
and proteins [22, 23]. Inflammatory mediators that are
derived from various tissues such as gut and adipose tissue
seem to play a role in the cascade of inflammation and fibrosis
of NASH.Within the adipose and liver tissues, increased lipid
storage, lipogenesis, and (adipo)cytokine synthesis occur as
stress signals for the endoplasmic reticulum (ER). Interest-
ingly, altered adipokine profiles have been suggested to play
a pivotal role in the progression of NASH [24]. Glucose-
dependent insulinotropic peptide (GIP) and glucagon-like
peptide-1 (GLP-1) are incretin hormones that are released by
the gastrointestinal tract in response to nutrients.The impair-
ment of incretins, which is observed classically in T2DM,
seems to have a role in the development of NASH because
it enhances IR and fat accumulation [25]. Bile acids are
other significant regulators of glucose homeostasis through
many signalling pathways that regulate the metabolism of
both glucose and cholesterol. Notably, in conditions such
as T2DM, the composition of bile acids is altered and a
decrease in the secretion of bile in the gut is observed;
consequently, a reduction in the secretion of GLP-1 and
impairment of glucose homeostasis may occur. Remarkably,
patients with NAFLD can show a hyperinsulinemic state that
definitively promotes lipogenesis and hepatic lipid deposition
and may also accelerate the development of liver disease [26,
27]. Many authors have suggested a significant connection
between altered cholesterol homeostasis and hepatic free
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cholesterol accumulation as a prompt for the pathogenesis
of NASH [28, 29]. Altered lipid metabolism is one of the
main stages of the pathogenesis of NASH, which leads to the
accumulation of intermediate products such as diacylglycerol
and phospholipids (e.g., sphingolipids and ceramides); these
are directly associated with fatty acid-induced toxicity and
IR.Thesemetabolites promote the activation ofmany kinases
that negatively regulate the insulin pathway [30]. Indeed,
the accumulation of free cholesterol in the ER membrane
decreases its fluidity and determines cellular stress and apop-
tosis [31, 32]. The role of gut microbiota in the pathogenesis
of NASH has generated a growing interest as modifications
in its composition could increase the permeability of the
gut and the translocation of bacterial endotoxins, which
may promote systemic inflammation and IR [33]. Bacterial
endotoxins, such as lipopolysaccharide (LPS), are a signif-
icant cause of hepatic neutrophil infiltration in the NASH
subjects [34]. Even if the LPS seems to have a relevant role
in the pathogenesis of NASH, the underlying mechanisms
are uncertain. Imajo et al. [35], through a mice-model study,
demonstrated that the upregulation of CD14 in Kupffer cells
by leptin-mediated signaling can determine hyperreactivity
against the endotoxins. Indeed, the authors showed that
hyperresponsivity against low-dose LPS, typically found in
the high-fat diet mice, can favour the NASH progression, in
terms of both inflammation and fibrosis.
2. Standard of Care: Lifestyle Interventions
NAFLD and NASH are linked to excess body weight, an
unhealthy diet, and inactive behaviours [13, 36, 37]. Notably,
disease progression from NAFL to NASH is basically stated
by obesity, T2DM, and metabolic syndrome, all of which are
associated with unhealthy activities [13]. According to this
view, all guidelines concur that lifestyle modifications are
the first-line approach to manage patients with NAFLD and
NASH [38–41]. However, while diet and exercise guidelines
for conditions such as T2DM and cardiovascular disease
are well established, no guidelines exist that indicate the
ideal diet and exercise modalities. Nevertheless, it is well
known that lifestyle coaching should involve a personalised
diet, physical activity, and cognitive-behaviour therapy [42].
In fact, diet and physical activity could support weight
loss, the recovery of liver enzymes, and an improvement in
histological alterations [43].
According to Promrat et al. [44], who reported interesting
data from a RCT, themain targets in patients who are affected
by NASH come from the “US Diabetes Prevention Program”
and are a weight loss of 7% and 150 minutes/week of physical
activity [45]. The authors enrolled patients with NASH and
evaluated the effects of lifestyle intervention using a combina-
tion of diet, exercise, and behaviour therapy. After 48weeks of
treatment, patients who received a lifestyle intervention lost
an average of 9.3% of their weight versus 0.2% in the con-
trols and demonstrated a significant reduction in “NAFLD
activity score.” Moreover, the score improvement correlated
significantly with weight reduction. In fact, a weight loss of
7% significantly decreased fat accumulation and improved
necroinflammation even if a significant effect on fibrosis was
not shown [44]. In a meta-analysis in 2010, Musso et al. [46]
confirmed that significant weight loss is safe and leads to
better histological and metabolic parameters in patients with
NASH. In particular, a 5% weight loss seems to decrease liver
steatosis and to ameliorate metabolic parameters, but higher
weight loss is likely necessary to downgrade the necroinflam-
mation and the overall disease activity. Notably, a gradual
weight loss (<1.6 kg/week) should be recommended because
faster weight loss might worsen the liver injury [47]. Eckard
et al. [48] conducted a RCT that involved 56 patients with a
biopsy-proven diagnosis of NAFLD. Subjects were assigned
to 1 of 4 lifestyle modification subgroups for 6 months:
standard care, low-fat diet and moderate exercise, moderate-
fat/low-processed-carbohydrate diet and moderate exercise,
or moderate exercise only. All subgroups demonstrated a
decrease in the “NAFLD activity score” over the 6-month
period with no significant difference between the subgroups.
In addition, in all groups a significant decrease was observed
in the Brunt grade and in the levels of ALT and AST. Among
patients with NASH at baseline, 53% improved their Brunt
grade or stage classification, and 25% had no criteria for
NASH at 6 months. Interestingly, no subgroup showed a
relevant weight loss greater than 5%. In this regard, physical
activity, if characterised by aerobic and resistance training,
shows an independent positive effect in the decrease of fat
in the liver, regardless of the weight loss [49, 50]. Moreover,
it should be considered that patients with NAFLD/NASH
are often at a high cardiovascular risk, and physical activity,
which is expected to improve cardiorespiratory fitness, is
important to decrease this hazard [51, 52]. In a thorough
review and analysis, Peng et al. [53] reported that the available
data are not enough to draw any conclusive results on the
proper lifestyle programme and that RCTs are necessary for
the evaluation of the beneficial and harmful effects of weight
reduction.
Centis et al. [42] analysed the motivation of patients
with metabolic liver disease when they changed their habits.
The authors demonstrated that a large number of subjects
experienced an inadequate inclination to change, particularly
with regard to physical activity. This low level of readiness
highlights the importance of the use of individually tailored
techniques. Notably, in this context, behavioural counselling
represents a central part of the therapeutic approach as it
affords patients with the information, self-efficacy, critical
thinking skills, and tools to realise a better lifestyle so that
their prognosis improves.
The lifestyle approach has at least two limits: the com-
pliance of the patients and the difficulty to present a unique
and clear scientific vision. In fact, lifestyle modifications can
be difficult to put into practice by the patient due to lack
of compliance or physical disability. Still, the best solution
in terms of nutrients for weight decrease and maintenance
remains unclear. Many accessible studies do not report
nutrient intake or physical activity and only record little
patient information. Studies of the lifestyle interventions in
patients with NAFLD/NASH show significant heterogeneity
in the enrolled subjects, and, thus, they report limited details
on the adherence to the lifestyle changes [54]. For all of
4 Gastroenterology Research and Practice
Table 1
Effects on Weight loss IR AST/ALT Histology Long-termmorbidity
Long-term
mortalityInflammation Fibrosis
Lifestyle interventions Yes Yes Yes Yes Unproven Unproven Unproven
Table 2
Effects on Weight loss IR AST/ALT Histology Long-termmorbidity
Long-term
mortalityInflammation Fibrosis
Vitamin E No No Yes Yes No Unproven Unproven
these reasons,more scientific energy should be devoted to the
improvement of this strong therapeutic tool (see Table 1).
3. First-Line Drug: Vitamin E
Vitamin E (RRR-𝛼-tocopherol) is an important lipid-soluble
antioxidant that is able to scavenge free radicals and avoid
lipid peroxidation. In recent years, the therapeutic effects
of vitamin E supplementation on NAFLD and NASH have
been investigated [55–57], and today, vitamin E should be
considered as a first-line pharmacotherapy for patients with
biopsy-proven NASH who do not have diabetes. On the
contrary, vitamin E is not recommended for the treatment of
NASH indiabetic patients, or in cases ofNAFLDwithout liver
biopsy, NASH with cirrhosis, or cryptogenic cirrhosis [41].
In a recent meta-analysis, Ji et al. [58] reported that
vitamin E supplementation might improve transaminase
levels in patients with NASH, which confirms the therapeutic
potential of vitamin E [58]. Sanyal et al. [56] developed
what is certainly the most relevant RCT with regard to the
use of vitamin E in patients with NASH. In their trial of
pioglitazone versus vitamin E versus placebo in which 247
adults with NASH were enrolled, vitamin E supplementation
(800 IU daily) for 96 weeks significantly improved steatosis
and inflammation and resolved the ballooning seen in adult
patients with NASHwho have aggressive disease. Specifically,
patients in the vitamin E arm showed a significantly better
histological improvement compared with those who received
the placebo.The transaminase level was decreased in patients
if it is assumed that both vitamin E and pioglitazone were
connected to the reductions of hepatic steatosis and lobular
inflammation. Notably, neither vitamin E nor pioglitazone
was associated with a significant improvement in fibrosis,
and pioglitazone led to an increase in weight compared with
vitamin E or placebo.
Validation is needed for the use of vitamin E in children,
and long-term RCTs are required to assess the long-term
efficacy and safety of vitamin E [59]. Finally, it should bemen-
tioned that a published meta-analysis [60] has suggested that
a high dose of vitamin E (>400 IU daily)may increase the risk
for all-cause mortality. Nevertheless, in this meta-analysis,
which included 19 trials, high-dosage trials (≥400 IU/d) were
smaller, on average, compared with others, and the studied
population was not homogeneous (see Table 2).
4. Second-Line Option: Pioglitazone
As IR is a well-known hallmark in the pathogenesis of
NASH, thiazolidinediones (pioglitazone and rosiglitazone)
were reported as possible therapeutic options.
Sanyal et al. [56] previously reported that pioglitazone
can lead to a decrease in AST and ALT levels and, from a
histological point of view, can decrease steatosis and lobular
inflammation. Other authors had previously described the
effects of pioglitazone on NASH with partial and doubtful
results. In two small, noncontrolled studies, Promrat et al.
and Lutchman et al. [61, 62] suggested that 48 weeks of
pioglitazone (30mg/day)may improveNASH both biochem-
ically and histologically. However, they also reported that
weight gain is a major side effect of the long-term use of
the pioglitazone and that this may significantly limit its use.
Through two stronger, double-blind RCTs, Belfort et al. [63]
and Aithal et al. [64] demonstrated that pioglitazone (45mg
daily for 24 weeks in the first study and 30mg daily for 48
weeks in the second) not only caused weight gain but also
enhanced tissue inflammation and fibrosis. In 2011, Musso et
al. [65] reported that pioglitazone could positively improve
liver histology and the cardiometabolic profile in the context
of NASH, but it also demonstrated the same impact with
respect to weight loss.
With regard to rosiglitazone, in 2008, Ratziu et al. [66]
published a RCT that suggested that the positive effect of
this drug on the AST/ALT levels and on liver steatosis led to
weight gain but had no significant effect on fibrosis.
In 2012, a meta-analysis on the use of pioglitazone and
rosiglitazone in the treatment of NASH was performed [67].
The authors reported that thiazolidinediones might decrease
ALT levels and improve histological parameters and that
pioglitazone might reverse fibrosis in NASH; however, this
latter effect represents the most important point of interest.
According to a recently published review article that
was conducted by an expert panel from the “Chilean
Gastroenterological Society” and the “Chilean Hepatology
Association” [68], pioglitazone together with vitamin E is
a proven pharmacological choice for patients with biopsy-
proven NASH, although evidence on its long-term safety
and efficacy is lacking. Additionally, the guidelines of the
American Association for the Study of Liver Diseases [41]
indicate pioglitazone as a possible therapeutic drug for the
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Table 3
Effects on Weight loss IR AST/ALT Histology Long-termmorbidity
Long-term
mortalityInflammation Fibrosis
Pioglitazone Opposite Yes Yes Yes Yes Unproven Unproven
Table 4
Effects on Weight loss IR AST/ALT Histology Long-termmorbidity
Long-term
mortalityInflammation Fibrosis
Metformin Yes Yes No No No Unproven Unproven
Table 5
Effects on Weight loss IR AST/ALT Histology Long-termmorbidity
Long-term
mortalityInflammation Fibrosis
UDCA No No No Yes No Unproven Unproven
treatment of NASH. However, the vast majority of patients
enrolled in the available studies did not have a diagnosis of
T2DM, and, therefore, data about its long-term efficacy and
safety are not available (see Table 3).
5. Broken Promises
5.1. Metformin. It is well known that metformin can
positively affect IR, which is a cornerstone of the pathogenesis
of NASH. Consequently, the possible role of this drug in
the treatment of metabolic liver disease has been extensively
studied. In 2004, Nair et al. [69] published a small open-
label trial and reported that a three-month therapy with
metformin was able to decrease the levels of ALT/AST but
that this positive effect was only transitory. Remarkably,
the authors reported a lack of significant improvement in
both liver inflammation and fibrosis. In a small pilot study,
Loomba et al. [70] showed that 48 weeks of metformin
(2.000mg/day) did not have any significant effect on
the histological features of NASH. In the following year,
Haukeland et al. [71] developed a more significant study. The
authors enrolled 48 patients with biopsy-proven NAFLD in
a RCT with metformin or placebo for 6 months. The absence
of histological changes as a result of the drug was confirmed,
but a decline in the serum levels of both lipids and glucose
was observed. Furthermore, in a RCT with metformin (500–
1000mg daily for 12months) versus placebo, Shields et al. [72]
corroborated the absence of a significant positive effect on
liver histology and also the lack of a significant weight loss. A
systematic review of 8 RCTs showed no favourable effects of
metformin on the histology of NASH although it can lead to
weight loss [73]. Indeed, although metformin can be used in
diabetic patients withNASH, no evidence exists to support its
efficacy in terms of the histology of NASH [74] (see Table 4).
5.2. Ursodeoxycholic Acid. Ursodeoxycholic acid (UDCA)
has beenwidely studied for the treatment of NASH for at least
three reasons: its antiapoptotic properties and its capacity to
decrease TNF-𝛼 and ER stress [75, 76]. Lindor et al. [77]
performed a RCT of 166 patients with liver biopsy-proven
NASH who were treated with 13–15mg/kg daily of UDCA
or placebo for 24 months. The authors found no difference
between the two arms in terms of histological improvement.
Still, because good outcomes that resulted from the use
of higher doses of UDCA were reported in liver disease
[78], some authors tried to use a high dosage approach.
Leuschner et al. [79] enrolled 185 patients with a histological
diagnosis of NASH in a RCT and offered them high-dose
UDCA (23–28mg/kg daily) or placebo for 18 months. The
authors reported a positive effect of the drug only on lobular
inflammation but did not demonstrate any positive effects on
fibrosis or on laboratory data. Ratziu et al. [80] developed a
RCT that included 126 subjects with biopsy-proven NASH
who were treated with 28–35mg/kg daily or placebo for 12
months.The authors demonstrated that a high dose ofUDCA
was more effective in terms of a decrease in ALT and indirect
indexes of fibrosis and IR, but the results were hampered
by a lack of serial biopsies. This latter aspect makes the
results of this study insufficient to justify the use of UDCA in
patients with NASH. This assumption is clearly reported in
the editorial by Haedrich and Dufour [81], who assumed that
UDCA given in a monotherapy at the usual dose shows no
positive effects in patients with NASH, and exerts only minor
effects at a higher dose. Moreover, the potentially damaging
adverse events that may occur during high-dose UDCA
treatment should be noted and considered (see Table 5).
5.3. Statins. Hyperlipidaemia (hypertriglyceridaemia, hyper-
cholesterolaemia, alone or together) is often associated with
obesity and T2DM and is present in 20–80% of patients
who are diagnosed with NASH [82, 83]. In NASH, the
plasma levels of lipids are increased and the accumulation of
triacylglycerol in the liver is a hallmark of the pathogenesis
of this disease [84]. In the same vein, it was reported
that statins, which are inhibitors of hydroxymethylglutaryl-
coenzyme A reductase, might be a valid therapeutic option
to decrease intrahepatic cholesterol and to improve the
abnormal metabolism of lipids [85].
In a well-written review that was published last year,
Eslami et al. [86] reported that only two studies concerned the
6 Gastroenterology Research and Practice
Table 6
Effects on Weight loss IR AST/ALT Histology Long-termmorbidity
Long-term
mortalityInflammation Fibrosis
Statins No No No No No Unproven Unproven
Table 7
Effects on Weight loss IR AST/ALT Histology Long-termmorbidity
Long-term
mortalityInflammation Fibrosis
Pentoxifylline No No Yes No No Unproven Unproven
use of statins in patients with NAFLD/NASH. These studies
showed the prerequisites for a concrete evaluation although
none of the available ones analysed the following relevant
outcomes: liver-related morbidity, liver-related mortality, or
all-cause mortality.
The first study was a trial that compared atorvastatin ver-
sus fenofibrate versus a combination of the two interventions
[87]. In this study, no differences with regard to plasma liver
enzyme activities or imaging findings were found, but when
these two outcomes were evaluated together, atorvastatin
appeared to be better than fenofibrate.
The other study was a small pilot trial that evaluated
simvastatin versus placebo [88]. The authors reported no
significant effects of simvastatin versus placebo in terms of
the levels of AST and ALT and in terms of liver histology.
The known side effects of statins, such as myositis, myal-
gia, rhabdomyolysis, elevations in aminotransferases, and
acute renal failure, are well described. However, the number
of adverse events was not significantly different between
groups in the two cited studies. Again, after a consideration
of other works that have proposed the use of statins in the
context of NASH, no adverse events were reported [89–91].
Indeed, statins, which seem to be safe in patients with
NASH, can be considered in particular situations such as
in patients with NAFLD/NASH who have increased serum
cholesterol levels. In this case, the increased cardiovascular
risk can independently indicate the use of these drugs [92]
(see Table 6).
5.4. Pentoxifylline. Pentoxifylline is amethylxanthine deriva-
tive and nonspecific phosphodiesterase inhibitor that is
usually used in the treatment of intermittent claudication for
its effects in the improvement of red blood cell flexibility,
decrease in blood viscosity, and enhancement of aerobic
glycolysis and oxygen consumption in ischaemic tissues [93].
Moreover, it was demonstrated that pentoxifylline decreases
gene transcription of TNF-𝛼, which influences multiple steps
of the cytokine/chemokine pathway [94]. Lee et al. [95]
proposed a small RCT that did not involve a histological
analysis; they compared pentoxifylline (1200mg daily for 3
months) and placebo and showed that the only positive effect
of the drug was on the AST level. In 2009, Rinella et al.
[96] published a RCT in which patients with NASH were
treated with pentoxifylline (1200mg daily for 12 months) or
placebo; the drug exerted a significant effect only on steatosis
and cellular ballooning. A few years later, Zein et al. [97]
developed a larger RCT that also included the histologi-
cal analysis. Pentoxifylline (1200mg daily for 12 months)
improved steatosis and tissue inflammation compared with
the placebo but did not show a significant influence on
fibrosis. In the same year, van Wagner et al. [98] published
a RCT with a similar structure as the previous trial and
reported no significant positive action of the drug either on
the biochemical data or on the liver histology. In 2011, a
systematic review that concerned the use of pentoxifylline in
patients with NASH [99] demonstrated that pentoxifylline
seems to decrease both AST and ALT levels but cannot
influence cytokine levels and histological aspects of NASH
(see Table 7).
5.5. Orlistat. Orlistat is an enteric lipase inhibitor that was
evaluated as a possible therapeutic choice for patients with
NAFLD/NASH since it was reported that it might lead to
weight reduction, decreased free fatty acid flux to the liver,
and improved insulin sensitivity, without hepatotoxic adverse
effects. This drug was studied in two RCTs in combination
with lifestyle modification. Zelber-Sagi et al. [100] proposed
a RCT in which patients were randomised to receive either
orlistat (120mg, 3 times daily for 6 months) or placebo; with
this drug, patients showed an improvement in ALT levels,
weight, and hepatic steatosis. However, these authors did not
analyse the modifications in liver histology. In another RCT,
Harrison et al. [101] randomised patients with biopsy-proven
NASH to a 1400 kcal/day diet and 800 IU vitamin E/day with
or without orlistat (the same dose with respect to the previous
study but for 9 months) and demonstrated no significant
improvement in AST/ALT levels, weight, insulin sensitivity,
and liver histology. Notably, patients who lost 5% or more
of their weight also experienced a reduction in steatosis,
IR, and plasma glucose, but only those subjects who lost
9% or more of their weight experienced an improvement in
necroinflammation as well (see Table 8).
6. Emerging Treatment Options
6.1. Vitamin E Associations. After consideration of the artic-
ulated and multifactorial pathogenesis of NASH, it is reason-
able to think that the combination of multiple drugs that are
directed at different targets may lead to a gain in terms of
effectiveness. The association of one molecule with one other
drug with a certain degree of scientific evidence is reasonable.
Indeed, vitamin E supplementation in combination with
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Table 8
Effects on Weight loss IR AST/ALT Histology Long-termmorbidity
Long-term
mortalityInflammation Fibrosis
Orlistat No No No No No Unproven Unproven
Table 9
Effects on Weight loss IR AST/ALT Histology Long-termmorbidity
Long-term
mortalityInflammation Fibrosis
Vitamin E/UDCA No No Yes Unproven Unproven Unproven Unproven
Table 10
Effects on Weight loss IR AST/ALT Histology Long-termmorbidity
Long-term
mortalityInflammation Fibrosis
ARBS Unproven Yes Unproven Unproven Unproven Unproven Unproven
other drugs has been widely used. In 2006, Dufour et al.
[102] published a RCT in which patients with NASH were
randomly allocated to receive UDCA (12–15mg/kg daily)
with vitamin E (800 IU daily), UDCA with placebo, or
placebo alone. The combination of UDCA and vitamin
E led to better serum levels of alanine aminotransferase
(ALT)/aspartate aminotransferase (AST) and liver steatosis in
comparison with UDCA monotherapy. Notably, the authors
did not exclude the possibility that, at a higher dosage,
UDCA might be more effective, and the absence of an
arm that included vitamin E plus placebo did not provide
information about the efficacy of vitamin E monotherapy.
The same study group [103] analysed the effects of UDCA-
vitamin E on adipokines and apoptosis of hepatocytes, which
demonstrated that this combination improved the levels of
transaminases as well as liver histology and decreased cellular
apoptosis. Pietu et al. [104], through a large retrospective
study, reported that the well-tolerated combination of UDCA
and vitamin E significantly improved ALT, AST, and gamma-
glutamyl transpeptidase levels, although the authors did not
evaluate the histological impact of this therapeutic approach.
In this context, a RCT that compares vitamin Emonotherapy
with vitamin E plus UDCA might be useful.
It was reported that the association of vitamins E and
C might reduce fibrosis in patients with NASH [105] as the
combination of vitamin E with other antioxidants would lead
to a regeneration of the oxidised form of the vitamin [106].
However, the lack of a RCT precludes the ability to accurately
evaluate this therapeutic choice [107] (see Table 9).
6.2. Angiotensin II Receptor Blockers. The role of the renin-
angiotensin system (RAS) in renal and cardiovascular
responses is well known. Angiotensin II receptor blockers
(ARBs) are a consolidated family of antihypertensive drugs.
However, other tissues produce RAS components that are
regulated independently from RAS in the circulatory system.
In the liver, chronic injury upregulates RAS in local tissues,
which seems to contribute to the vicious cycle of steatosis-
necroinflammation-fibrosis. Indeed, many authors suggest
that ARBs may be useful in the treatment of NAFLD/NASH.
It was reported that losartan has an antifibrotic effect
and improves steatosis and necroinflammation in patients
affected by NASH [108, 109]. Interestingly, Torres et al.
[110] proposed the use of losartan for NASH in a RCT
(rosiglitazone versus rosiglitazone and metformin versus
rosiglitazone and losartan) but found no significant results.
On the contrary, the use of telmisartan shows the longest
terminal elimination half time and the greatest affinity for
the angiotensin II receptor type 1 among the ARBs. It was
reported in animal models that this drug reduced weight,
improved hyperinsulinaemia, and decreased triglycerides,
steatosis, fibrosis, and liver macrophage infiltration [111–114].
Interestingly, Clemenz et al. [115] also indicated telmisartan as
a partial PPAR-alpha agonist, which suggests that it causes a
reduction of circulating and hepatic triglycerides. Georgescu
et al. [116] first demonstrated that telmisartan (20mg daily)
was better than valsartan for the improvement of IR and liver
histology (i.e., steatosis, lobular inflammation, ballooning,
and fibrosis), and its action on IR was confirmed by Miura
et al. [117]. With regard to its safety, Schumacher and Mancia
[118] retrospectively analysed 50 studies on telmisartan and
showed that it has a placebo-like tolerability. Indeed, among
theARBs, telmisartan is themost promising for the treatment
ofNASH in terms of both safety and efficacy on inflammation
and fibrosis; however, the lack of a large RCT precludes the
use of this drug as a consolidated option (see Table 10).
6.3. Pre- and Probiotics. It was demonstrated that bacterial
overgrowth in the bowel is present in 50% of patients with
NASH [119]. Moreover, a high-fat diet-induced obesity is
related to changes in the composition of intestinal bacteria
[120]. Indeed,modifications of the intestinal bacterial content
might be involved in the pathogenesis of NASH through the
enhancement of intestinal permeability, the direct activation
of inflammatory cytokines, and the improvement of the
absorption of endotoxins [121].
Aller et al. [122] proposed a double-blind RCT in
which patients with metabolic liver disease were treated
with 500 million Lactobacillus bulgaricus and Streptococcus
thermophilus or placebo. Patients in the drug arm showed
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Table 11
Effects on Weight loss IR AST/ALT Histology Long-termmorbidity
Long-term
mortalityInflammation Fibrosis
Pre- and probiotics No Yes Yes Unproven Unproven Unproven Unproven
Table 12
Effects on Weight loss IR AST/ALT Histology Long-termmorbidity
Long-term
mortalityInflammation Fibrosis
Fatty acid-bile Unproven Unproven Unproven Unproven Unproven Unproven Unproven
an improvement in ALT/AST levels but did not show effects
in terms of anthropometric parameters and cardiovascular
risk factors. Malaguarnera et al. [123] evaluated the effects of
Bifidobacterium longum, fructooligosaccharides, and lifestyle
modification versus lifestyle modification alone, for the
treatment of NASH. In this RCT, the authors showed that
Bifidobacterium longum together with fructooligosaccharides
significantly decreased TNF-𝛼, C-reactive protein, AST lev-
els, IR, serum endotoxin levels, steatosis, and the “NASH
activity index.” Finally, Wong et al. [124] tested a Lepicol
probiotic formula (Lactobacillus plantarum, Lactobacillus del-
brueckii, Lactobacillus acidophilus, Lactobacillus rhamnosus,
and Bifidobacterium bifidum) in a small trial to cure patients
with biopsy-proven NASH.The authors obtained a reduction
in liver fat, as measured by proton-magnetic resonance
spectroscopy, and a decrease in AST levels.
In a meta-analysis published in 2013 [125], it was sug-
gested that probiotics might significantly decrease the levels
of ALT, AST, total cholesterol, TNF-𝛼, and IR and exert
virtually positive effects on the pathogenesis of NASH (see
Table 11).
6.4. Fatty Acid-Bile. Bile acids, but not UDCA, control
metabolism by binding to the nuclear hormone receptor
farnesoid X and to a transmembrane bile acid receptor.
Stimulation of the farnesoid X receptor could increase
insulin sensitivity and decrease both glucose and lipids.
Transmembrane bile acid receptors are regulators of glucose
homeostasis and lipid metabolism, and activation of these
receptors stimulates energy expenditure and protects against
obesity. Farnesoid X receptor agonists were proposed as
possible treatment options for metabolic disorders such as
T2DM, hypertriglyceridaemia, certain cases of cholestasis,
and cholesterol gallstone disease [126]. Indeed, bile acids are
metabolic integrators and are not solely regulators of bile-acid
homeostasis. As a consequence, non-UDCAbile acids should
also be considered in the context of NAFLD and NASH
[127]. Similarly, Mudaliar et al. [128] developed a double-
blind, placebo-controlled, proof-of-concept study on the use
of obeticholic acid in patients with NASH and T2DM. Six
weeks of therapy with this drug led to an improvement in
IR and a decrease in the indirect index of liver inflammation
and fibrosis. More recently, Neuschwander-Tetri et al. [129]
developed a multicentre, double-blind, placebo-controlled
trial, enrolling patients affected by NASH. Authors proposed
a 72-week treatment with obeticholic acid (25mg daily,
orally). Patients in the drug arm with respect to those in the
placebo one showed an improvement in themain histological
features of NASH. However, as the same authors reported,
data about the long-term benefit and safety of this drug are
today not available (see Table 12).
6.5. Omega-3. It was reported that natural fatty acids such
as long-chain omega-3 (LCn-3) polyunsaturated fatty acids
(PUFAs), including eicosapentaenoic acid and docosahex-
aenoic acid, show bioactive properties; therefore, these are
a potential treatment option for patients with NASH [130].
LCn-3 PUFA supplementation is a promising treatment for
patients with NAFLD/NASH as it can affect different aspects
of this complex disease. Animal studies and preliminary
clinical trials have demonstrated that purified n-3 supple-
mentation or fish intake might prevent or reverse the rate of
NASH [131]. Notably, the therapeutic effects of LCn-3 PUFAs
were verified in three studies, two of which included patients
with NAFLD [132, 133] and one of which evaluated subjects
with NASH [134]. In the latter study, 1 year of treatment
with eicosapentaenoic acid significantly improved steatosis
(imaging and histological) as well as the levels of AST/ALT,
cholesterol, iron, and free fatty acids but did not have any
effect on IR. Markedly, the lack of a control group and the
small sample size do not allow for significant conclusions (see
Table 13).
6.6. L-Carnitine. L-Carnitine is a modulator of mitochon-
drial free fatty acid transport and oxidation that has demon-
strated a significant effect on oxidative stress, activation of
immune cells, and the integrity of the epithelial barrier.
Interestingly, a potential therapeutic value was reported for
the use of L-carnitine supplementation in cases of intestinal
inflammation [135]. On the assumption that liver steatosis is
a common pattern of both hepatitis C and NAFLD/NASH, a
total of 70 affected patients were randomly assigned to receive
interferon and ribavirin alone or plus carnitine; the patients
in this second arm showed a relevant decrease in steatosis
[136].
In a high quality RCT conducted by Malaguarnera et
al. [137], patients with NASH and control subjects were
randomly treated with L-carnitine plus modified diet or
modified diet alone. L-Carnitine plus lifestyle intervention
for 6 months improved steatosis, the “NASH activity score,”
AST/ALT levels, IR, plasma glucose, and total and low-
density lipoprotein cholesterol.
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Table 13
Effects on Weight loss IR AST/ALT Histology Long-termmorbidity
Long-term
mortalityInflammation Fibrosis
Omega-3 Unproven Unproven Unproven Unproven Unproven Unproven Unproven
Table 14
Effects on Weight loss IR AST/ALT Histology Long-termmorbidity
Long-term
mortalityInflammation Fibrosis
L-Carnitine Unproven Unproven Unproven Unproven Unproven Unproven Unproven
The results of this supplementation therapy are very
interesting and need to be confirmed in a large and well-
structured RCT that tests the efficacy of L-carnitine used
alone or with other drugs (see Table 14).
7. Conclusions and Future Perspectives
NASH will continue to be the most common liver-related
health problem in the future. In fact, the emerging direct
antiviral therapies for hepatitis C and the well-consolidated
drugs for hepatitis B will allow these liver diseases to be treat-
able in a vastmajority of cases. On the contrary, the best treat-
ment modalities for fatty liver disease together with alcohol-
related disease have yet to be elucidated. Today, the incidence
of NAFLD and NASH is increasing in industrialised and
emerging countries, and this increase is strictly connected to
the increase in obesity, visceral obesity, T2DM, IR, and arte-
rial hypertension. In the pathogenesis of NASH, according to
themost recent view,many events occur in parallel, and all are
potential therapeutic targets. The principally studied actors
are the following: IR, oxidative stress, gut, adipose and pan-
creas tissues, altered lipid metabolism, bile acids, gut micro-
biota, systemic chronic inflammation, and genetic patterns.
Today, the standard of care for the treatment of NASH is
lifestyle modification. However, its effect on liver histology
in patients with NASH warrants further evaluation, as the
lack of evidence regarding the optimal dietary nutrient
composition and exercise is a significant ongoing problem.
Moreover, a vast majority of patients show a lack of compli-
ance with diet and exercise programs due to their attitudes
or physical inability. Currently, the first-line pharmacological
approaches for NASH are vitamin E and pioglitazone as they
are unique drugs that have provided a sufficient degree of
evidence in terms of efficacy. In particular, both vitamin
E and pioglitazone improve the levels of transaminases, fat
accumulation, and liver inflammation. However, these two
drugs also display evident limits. In particular, vitamin E has
not been proven to have an effect on fibrosis or on the long-
term morbidity and mortality, and its possible use is limited
to patients without T2DM. With regard to pioglitazone, its
main restriction is its negative impact on weight. In addition,
the safety of this drug remains uncertain as data about the
long-term use of vitamin E or pioglitazone are not available.
On the one hand, many drugs have been tested through
RCTs, which showed only a few relevant results in terms of
efficacy, such as metformin, UDCA, statins, pentoxifylline,
and orlistat. On the other hand, many emerging treatment
options can be found in the literature. Among them, in our
opinion, themost attention should be focused on telmisartan,
a safe antihypertensive drug.This drug, although it has not yet
been tested in a large and well-structured RCT, seems to have
a significant impact on IR, liver steatosis, inflammation, and
liver fibrosis according to preliminary studies. Additionally
L-carnitine is a particularly promising supplement that could
be evaluated alone or in association with other drugs.
In the complex establishment of a study on NASH, some
aspects should be improved with respect to the available
papers. Lifestyle intervention should be clearly defined as
it needs to represent a clear point of comparison with
respect to newly proposed drugs. In addition, we suggest that
the lifestyle intervention itself has a significant potential to
expand as specific and widely accepted alimentary, exercise,
and counselling indications do not actually exist. Future
RCTs need to include histological endpoints and an adequate
duration and should also consider patients with advanced
fibrosis. Notably, an adequate follow-up period will allow
for the assessment of the long-term efficacy and safety of
the proposed treatments and for the evaluation of strong
outcomes such as the development of cirrhosis andhepatocel-
lular carcinoma, the morbidity and liver, cardiovascular, and
all-cause mortality.
Today, many authors continue to develop RCTs with dif-
ferent agents in order to cure patients withNASH andNASH-
related fibrosis [138]. However, because multiple parallel
roads characterise the complex pathogenesis of NASH, we
suggest the evaluation of the combination of different drugs
that could act synergistically on the onset and progression
of this disease. According to this view, the development of
individualised treatment would be opportune. Consequently,
the experimental use of vitamin E and UDCA without
obvious positive results was a good course of action.
In conclusion, many aspects with regard to therapy for
patients with NASH should be implemented. In particular,
lifestyle interventions should be clearly defined and opti-
mised, the individualisation of a pharmacological approach
with associations of different drugs might be tested, and large
RCTs with histological outcomes and long-term observations
should be developed.
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